tetano
Editor, Senior Moderator
J Clin Med
. 2022 Dec 2;11(23):7172.
doi: 10.3390/jcm11237172.
Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece
Marios Spanakis[SUP] 1 2 [/SUP], Petros Ioannou[SUP] 3 [/SUP], Sotiris Tzalis[SUP] 3 [/SUP], Vasiliki Papakosta[SUP] 3 [/SUP], Evridiki Patelarou[SUP] 1 [/SUP], Nikos Tzanakis[SUP] 4 [/SUP], Athina Patelarou[SUP] 1 [/SUP], Diamantis P Kofteridis[SUP] 3 [/SUP]
Affiliations
Abstract
The modulation of the pharmacological action of drugs due to drug-drug interactions (DDIs) is a critical issue in healthcare. The aim of this study was to evaluate the prevalence and the clinical significance of potential DDIs in patients admitted to the University Hospital of Heraklion in Greece with coronavirus disease 2019 (COVID-19). Cardiovascular disorders (58.4%) and diabetes (types I and II) (29.6%) were the most common comorbidities. A high occurrence of DDIs was observed, and clinically significant DDIs that may hamper response to treatment represented 40.3% of cases on admission, 21% during hospitalization, and 40.7% upon discharge. Polypharmacy and comorbidities were associated with a higher prevalence of DDIs in a statistically significant way (p < 0.05, 95% CI). Clinically significant DDIs and increased C-reactive protein values upon admission were associated with prolonged hospitalization. The results reveal that patients admitted due to COVID-19 in Greece often have an additional burden of DDIs that healthcare teams should approach and resolve.
Keywords: COVID-19; SARS-CoV-2; adverse drug reactions; drug-drug interactions; pharmacotherapy.
. 2022 Dec 2;11(23):7172.
doi: 10.3390/jcm11237172.
Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece
Marios Spanakis[SUP] 1 2 [/SUP], Petros Ioannou[SUP] 3 [/SUP], Sotiris Tzalis[SUP] 3 [/SUP], Vasiliki Papakosta[SUP] 3 [/SUP], Evridiki Patelarou[SUP] 1 [/SUP], Nikos Tzanakis[SUP] 4 [/SUP], Athina Patelarou[SUP] 1 [/SUP], Diamantis P Kofteridis[SUP] 3 [/SUP]
Affiliations
- PMID: 36498745
- DOI: 10.3390/jcm11237172
Abstract
The modulation of the pharmacological action of drugs due to drug-drug interactions (DDIs) is a critical issue in healthcare. The aim of this study was to evaluate the prevalence and the clinical significance of potential DDIs in patients admitted to the University Hospital of Heraklion in Greece with coronavirus disease 2019 (COVID-19). Cardiovascular disorders (58.4%) and diabetes (types I and II) (29.6%) were the most common comorbidities. A high occurrence of DDIs was observed, and clinically significant DDIs that may hamper response to treatment represented 40.3% of cases on admission, 21% during hospitalization, and 40.7% upon discharge. Polypharmacy and comorbidities were associated with a higher prevalence of DDIs in a statistically significant way (p < 0.05, 95% CI). Clinically significant DDIs and increased C-reactive protein values upon admission were associated with prolonged hospitalization. The results reveal that patients admitted due to COVID-19 in Greece often have an additional burden of DDIs that healthcare teams should approach and resolve.
Keywords: COVID-19; SARS-CoV-2; adverse drug reactions; drug-drug interactions; pharmacotherapy.